Aptorum Group Ltd Stock Price, News & Analysis

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology, autoimmune diseases, and infectious diseases. CEO Darren Lui will present at the H.C. Wainwright Global Investment Conference in New York from September 13-16, 2022. The company will also hold one-on-one meetings with institutional investors, emphasizing its ongoing clinical trials and drug development initiatives. For registration, visit H.C. Wainwright.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) will be featured in an exclusive interview on The RedChip Money Report airing on Bloomberg TV on August 20, 2022, at 7 p.m. ET. The interview, conducted by CEO Darren Lui, will cover the company’s novel therapeutics, diagnostic products, and U.S. patent grants. Targeting unmet medical needs in oncology, autoimmune, and infectious diseases, Aptorum is advancing its therapeutic assets and diagnostic technologies, enhancing its presence in the biopharmaceutical sector.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical firm, announced that President Darren Lui will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company focuses on developing therapies for unmet medical needs in oncology and infectious diseases. Additionally, Aptorum will conduct online one-on-one meetings with institutional investors during the event. For more details, visit www.aptorumgroup.com.

Aptorum Group Limited (Nasdaq: APM) announced encouraging results from its finalized Phase 1 clinical trial of SACT-1, targeting Neuroblastoma. The trial, conducted with healthy volunteers, demonstrated good safety and tolerability at a 150mg dosage, with no serious adverse events reported. Key bioavailability metrics showed significant improvements under fed conditions, with AUC ratios over 189%. Aptorum plans to meet with the US FDA for a Phase 1b/2a trial application, aiming to initiate testing in pediatric neuroblastoma patients.

Aptorum Group Limited (Nasdaq: APM) reported significant changes in fiscal year results, with a net loss of $27.1 million in 2021 compared to a net income of $4.9 million in 2020, mainly due to a loss on securities investments. The company is progressing in clinical trials for its lead projects, including ALS-4 and SACT-1, with plans to submit an IND application and initiate a Phase 1b/2a study. Additionally, Aptorum aims to commercialize its NativusWell® health supplement in Asia and Europe, pending registration completion.

Aptorum Group Limited (Nasdaq: APM) has received a patent from the US Patent and Trademark Office for its Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics (RPIDD) technology, which offers a unique approach to DNA library preparation. This method significantly enhances the speed and simplicity of diagnostics for infectious diseases. Aptorum has an exclusive licensing agreement with Singapore's A*STAR institution for this technology. The company aims to expedite the clinical validation and pre-commercialization of RPIDD, which could transform clinical diagnostics and improve patient outcomes.

Aptorum Group (Nasdaq: APM) announced an interview with President Darren Lui on The RedChip Money Report® airing on Bloomberg TV on April 23 at 7 p.m. ET. The company is focused on developing drugs for oncology and infectious diseases and is advancing its drug discovery platforms. This includes co-developing rapid pathogen identification technology. The interview will reach approximately 73 million homes in the U.S., highlighting the company's efforts and developments in the biopharmaceutical sector.

Aptorum Group (Nasdaq: APM) announced that its drug candidate SACT-1 has received Orphan Drug Designation from the FDA for treating neuroblastoma. This designation supports Aptorum's plan to file an Investigational New Drug Application (IND) for a Phase 1b/2a clinical trial in 2022. Neuroblastoma, a serious pediatric cancer, has a 5-year survival rate of 40-50% for high-risk patients. The SACT-1 compound aims to enhance tumor cell death and can be used alongside standard chemotherapy, moving forward Aptorum's commitment to addressing unmet medical needs in oncology.

Aptorum Group (NASDAQ: APM) has announced the granting of its first patent for SACT-1, a repurposed drug aimed at treating various cancers, including neuroblastoma. This patent, numbered 11,166,962 B2, provides intellectual property protection for the drug's composition and its method of use in conjunction with other treatments. The company also revealed plans to pursue further patent protection and initiate Phase Ib/2a clinical trials for SACT-1 pending IND clearance. This milestone is crucial for protecting their investment and advancing their oncology pipeline.